Ferring Pharmaceuticals
 |
|
|
Formerly called
|
Nordiska Hormon Laboratoriet |
|---|---|
| Private limited company | |
| Traded as | not traded |
| Industry | Pharmaceuticals |
| Founded | 1950 |
| Headquarters | Saint Prex, Switzerland |
|
Area served
|
Worldwide |
|
Key people
|
|
| Products | See below |
|
Number of employees
|
7,000 |
| Subsidiaries |
www |
| Website | www |
Ferring Holding SA, better known as Ferring Pharmaceuticals, is a multinational pharmaceutical company that specializes in the development and marketing of drugs for use in human medicine.
The company was founded by Frederik Paulsen Sr in Malmö, Sweden, in 1950, initially as the Nordiska Hormon Laboratoriet, renamed Ferring in 1954. A ferring in Frisian is a person from the island Föhr off the western coast of Germany. Mr. Paulsen's family originates from that island.
The first major breakthrough was the synthetic production of and vasopressin in 1961. With further growth and expansion, the headquarters moved to Copenhagen, Denmark, and subsequently to Switzerland.
In August 2016, the company announced it would acquire the phase III sciatica candidate drug - Condoliase (SI-6603) from Seikagaku for approximately $95 million.
Ferring Holding SA headquarters are located in Saint-Prex, Switzerland. The company holds over 5,000 employees with manufacturing facilities in Europe, South America, China and has built two new facilities in the US and in India.
In Copenhagen, Ferring has a R&D centre in the Ferring Tower in Ørestad. The company has commissioned Foster and Partners to design a new building in the Scanport development which is expected to be completed in 2019. It will have area of 30,000 square metres and have room for 750 employees.
...
Wikipedia